4-Methylesculetin ameliorates LPS-induced depression-like behavior through the inhibition of NLRP3 inflammasome.
4-methylesculetin
NLRP3 inflammasome
anti-depressant activity
cytokines
lipopolysaccharide
Journal
Frontiers in pharmacology
ISSN: 1663-9812
Titre abrégé: Front Pharmacol
Pays: Switzerland
ID NLM: 101548923
Informations de publication
Date de publication:
2023
2023
Historique:
received:
10
12
2022
accepted:
07
02
2023
entrez:
13
3
2023
pubmed:
14
3
2023
medline:
14
3
2023
Statut:
epublish
Résumé
The pathophysiology of depression is heavily dependent on inflammation. Evidence suggests that the etiology of depression is linked with NLRP3 inflammasome-induced inflammation. Therefore, blocking the activated NLRP3 inflammasome may be beneficial for treating depression. Due to the limitations of currently available antidepressants, it is necessary to develop novel, safe, and affordable drugs for the treatment of depression. A natural coumarin derivative named 4-methylesculetin (4-MESC) possesses anti-inflammatory properties. However, the role of 4-MESC as an antidepressant has not been elucidated. Therefore, in this study, we explored the antidepressant-like effects of 4-MESC and its underlying molecular mechanism through the modulation of the NLRP3 inflammasome. The docking and molecular dynamic simulation studies revealed that 4-MESC has a higher affinity for the NLRP3 PYD. Blood-brain barrier permeability was confirmed using the SwissADME pharmacokinetic tool. High doses (50 mg/kg) of 4-MESC significantly reduced the immobility duration in the tail-suspension test (TST) and forced swim test (FST) without changing the overall locomotor activity in the female Swiss albino mice that were subjected to lipopolysaccharide (LPS). LPS-induced pro-inflammatory cytokines such as IL-6 and TNF-α were reduced in serum and brain tissues using 4-MESC. 4-MESC's neuroprotective effects are mediated by increased brain-derived neurotrophic factor (BDNF) and decreased cortisol levels. 4-MESC markedly reduced LPS-induced elevated levels of ROS and lipid peroxidation (malondialdehyde levels) and enhanced the superoxide dismutase (SOD) activity and glutathione levels, which revealed its anti-oxidant potential against oxidative stress. 4-MESC diminished the expression levels of NF-κBp65, IL-6, NLRP3, caspase-1, gasdermin D, and IL-1β in the hippocampus. These findings demonstrated that 4-MESC exhibited antidepressant-like effects by inhibiting the NLRP3 inflammasome. However, other antidepressant mechanisms might also be involved which require further studies.
Identifiants
pubmed: 36909194
doi: 10.3389/fphar.2023.1120508
pii: 1120508
pmc: PMC9995395
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1120508Informations de copyright
Copyright © 2023 Choudhary, Prasad, Lokhande, Murti, Singh, Ravichandiran and Kumar.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Int J Mol Sci. 2013 Jul 08;14(7):14105-18
pubmed: 23880858
Science. 1987 Oct 23;238(4826):519-21
pubmed: 2821620
Psychol Bull. 2014 May;140(3):774-815
pubmed: 24417575
Arch Gen Psychiatry. 2007 Mar;64(3):327-37
pubmed: 17339521
Chem Biol Interact. 2010 Jul 30;186(2):211-8
pubmed: 20380826
Lancet. 2021 Nov 6;398(10312):1700-1712
pubmed: 34634250
Front Neuroendocrinol. 2009 Jan;30(1):30-45
pubmed: 19017533
Biochimie. 2013 Jun;95(6):1326-35
pubmed: 23485680
Biol Psychiatry. 1992 Aug 15;32(4):354-63
pubmed: 1420649
Neuropsychopharmacology. 2010 Dec;35(13):2510-20
pubmed: 20827273
Brain Behav Immun. 2014 Oct;41:90-100
pubmed: 24859041
Lancet. 2018 Nov 24;392(10161):2299-2312
pubmed: 30396512
Behav Brain Res. 2019 May 17;364:494-502
pubmed: 28572058
J Biomol Struct Dyn. 2021 Nov;39(18):7294-7305
pubmed: 32815481
Depress Res Treat. 2020 Oct 17;2020:7024275
pubmed: 33133693
Curr Drug Metab. 2008 Sep;9(7):622-7
pubmed: 18781914
Neuroreport. 2018 Jan 17;29(2):134-140
pubmed: 29206699
Nature. 1995 Mar 30;374(6521):450-3
pubmed: 7700353
Chem Biol Interact. 2020 Jan 5;315:108876
pubmed: 31669340
Eur J Immunol. 2010 Mar;40(3):616-9
pubmed: 20201014
Indian J Exp Biol. 2006 Oct;44(10):816-20
pubmed: 17131912
Cell. 2010 Mar 19;140(6):821-32
pubmed: 20303873
Pharmacol Res. 2017 Jul;121:114-121
pubmed: 28465217
Mol Neurobiol. 2016 Sep;53(7):4874-82
pubmed: 26362308
Mol Neurobiol. 2021 May;58(5):2407-2422
pubmed: 33421016
J Child Adolesc Psychopharmacol. 2016 Oct;26(8):727-732
pubmed: 26771135
Sci Rep. 2020 Apr 16;10(1):6493
pubmed: 32300192
Brain Res. 2020 Oct 1;1744:146917
pubmed: 32474018
Brain Behav Immun. 2016 Aug;56:175-86
pubmed: 26928197
ACS Chem Neurosci. 2020 May 20;11(10):1495-1503
pubmed: 32364698
CNS Neurosci Ther. 2014 Mar;20(3):294-5
pubmed: 24479787
Brain Behav Immun. 2013 Jul;31:105-14
pubmed: 23261775
Nat Rev Immunol. 2016 Jan;16(1):22-34
pubmed: 26711676
Chem Biol Interact. 2012 Jan 5;195(1):76-85
pubmed: 22119283
J Neurochem. 2004 Feb;88(4):939-47
pubmed: 14756815
CNS Neurosci Ther. 2014 Feb;20(2):119-24
pubmed: 24279434
Biochim Biophys Acta. 2016 Dec;1863(12):2977-2992
pubmed: 27646922
Nat Rev Neurosci. 2008 Jan;9(1):46-56
pubmed: 18073775
Front Immunol. 2020 Feb 18;11:211
pubmed: 32133002
Mol Aspects Med. 2009 Feb-Apr;30(1-2):1-12
pubmed: 18796312
Eur J Pharmacol. 2004 Oct 1;500(1-3):371-84
pubmed: 15464046
J Clin Psychiatry. 2004 Jul;65(7):959-65
pubmed: 15291685
J Immunol. 2009 Jul 15;183(2):787-91
pubmed: 19570822
Mol Biol Rep. 2020 Oct;47(10):7709-7722
pubmed: 32959196
Am J Psychiatry. 1993 Aug;150(8):1189-93
pubmed: 8328562
Molecules. 2020 Sep 07;25(18):
pubmed: 32906766
Biol Psychiatry. 2002 Sep 1;52(5):381-5
pubmed: 12242053
Mediators Inflamm. 2013;2013:271359
pubmed: 23935246
Brain Behav Immun. 2014 Feb;36:111-7
pubmed: 24513871